Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).

Lucero, Josephine; Al-Harbi, Salman; Yee, Karen W L

Lucero, Josephine; Al-Harbi, Salman; Yee, Karen W L.

Afiliación

Lucero J; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, 700 University Avenue, 6th Floor, Toronto, ON M5G 1Z5, Canada.
Al-Harbi S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, 700 University Avenue, 6th Floor, Toronto, ON M5G 1Z5, Canada.
Yee KWL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, 700 University Avenue, 6th Floor, Toronto, ON M5G 1Z5, Canada.

Curr Oncol ; 30(7): 6177-6196, 2023 06 27.

Article en En | MEDLINE | ID: mdl-37504319

Asunto(s)

Síndromes Mielodisplásicos; Neoplasias; Humanos; Pronóstico; Síndromes Mielodisplásicos/terapia; Lenalidomida/uso terapéutico; Riesgo; Factores Inmunológicos/uso terapéutico; Neoplasias/tratamiento farmacológico

Palabras clave

antithymocyte globulin; hypomethylating agent; imetelstat; lenalidomide; luspatercept; myelodysplastic neoplasm; prognostic scoring system

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Neoplasias Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Curr Oncol Año: 2023 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google